New oral anticoagulants compared to warfarin for perioperative anticoagulation in patients undergoing atrial fibrillation catheter ablation: a meta-analysis of continuous or interrupted new oral anticoagulants during ablation compared to interrupted or continuous warfarin

Journal of Interventional Cardiac Electrophysiology

Volumn 48, Issue 3, 2017, Pages 267-282

  Zhao, Yue ^a   Yang, Yuan ^a   Tang, Xuejiao ^a   Yu, Xiang ^a   Zhang, Lei ^a   Xiao, Hua ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Anticoagulants; Atrial fibrillation; Catheter ablation; Complications

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; NEW ORAL ANTICOAGULANT; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN;

ACTIVATED COAGULATION TIME; ANTICOAGULATION; ATRIAL FIBRILLATION; BLEEDING; BLOOD CLOTTING TIME; CATHETER ABLATION; CHEMOTHERAPY; CONTINUOUS DRUG THERAPY; DATA EXTRACTION; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; INTERRUPTED DRUG THERAPY; MAJOR BLEEDING; META ANALYSIS; MINOR BLEEDING; PERIOPERATIVE ANTICOAGULATION; PUBLISHING; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; THROMBOEMBOLISM; CAUSALITY; COMORBIDITY; COMPARATIVE STUDY; FEMALE; HEMORRHAGE; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATIONS; PREVALENCE; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; CAUSALITY; COMORBIDITY; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PREVALENCE; RISK FACTORS; WARFARIN;

EID: 85009285398     PISSN: 1383875X     EISSN: 15728595     Source Type: Journal    
DOI: 10.1007/s10840-016-0221-7     Document Type: Review

References (41)

1. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14(10):1385–413.
2. Santangeli P, Di Biase L, Horton R, Burkhardt JD, Sanchez J, Al-Ahmad A, et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis. Circ Arrhythm Electrophysiol. 2012;5(2):302–11.
3. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013;368(22):2084–93.
4. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland Jr JC, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104.
5. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.
6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.
7. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.
8. Schulman S. Advantages and limitations of the new anticoagulants. J Intern Med. 2014;275(1):1–11.
9. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15(5):625–51.
10. Kim JS, She F, Jongnarangsin K, Chugh A, Latchamsetty R, Ghanbari H, et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm. 2013;10(4):483–9.
11. Kaseno K, Naito S, Nakamura K, Sakamoto T, Sasaki T, Tsukada N, et al. Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. Circ J. 2012;76(10):2337–42.
12. Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2012;59(13):1168–74.
13. Providencia R, Albenque JP, Combes S, Bouzeman A, Casteigt B, Combes N, et al. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Heart. 2013;100(4):324–35.
14. Shurrab M, Morillo CA, Schulman S, Kansal N, Danon A, Newman D, et al. Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis. Can J Cardiol. 2013;29(10):1203–10.
15. Steinberg BA, Hasselblad V, Atwater BD, Bahnson TD, Washam JB, Alexander JH, et al. Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. J Interv Card Electrophysiol. 2013;37(3):213–21.
16. Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol. 1998;51(12):1235–41.
17. Wells. G, Shea. B, Od’Connell. D, Peterson. J, Welch. V, Losos. M, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed 31 Aug 2015.
18. Agarwal MB, Verma S, Mahapatra M, Tripathi AK, Bhave A, Deshpande A, et al. Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants. Indian J Hematol Blood Transfus. 2012;28(3):129–43.
19. Arshad A, Johnson CK, Mittal S, Buch E, Hamam I, Tran T, et al. Comparative safety of periablation anticoagulation strategies for atrial fibrillation: data from a large multicenter study. Pacing Clin Electrophysiol. 2014;37(6):665–73.
20. Kochhäuser S, Khaykin Y, Beardsall J, Juta R, Hache P, Trought K, et al. Comparison of outcomes after cardioversion or atrial fibrillation ablation in patients with differing periprocedural anticoagulation regimens. Can J Cardiol. 2014;30(12):1541–6.
21. Providencia R, Marijon E, Albenque JP, Combes S, Combes N, Jourda F, et al. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. Europace. 2014;16(8):1137–44.
22. Armbruster HL, Lindsley JP, Moranville MP, Habibi M, Khurram IM, Spragg DD, et al. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. Ann Pharmacother. 2014;49(3):278–84.
23. Homoud MK. In catheter ablation of AF, continuing vs interrupting warfarin reduced periprocedural thromboembolic events. Ann Intern Med. 2014;161(12):Jc12.
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
25. Snipelisky D, Kauffman C, Prussak K, Johns G, Venkatachalam K, Kusumoto F. A comparison of bleeding complications post-ablation between warfarin and dabigatran. J Interv Card Electrophysiol. 2012;35(1):29–33.
26. Kaiser DW, Streur MM, Nagarakanti R, Whalen SP, Ellis CR. Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter. J Interv Card Electrophysiol. 2013;37(3):241–7.
27. Imamura K, Yoshida A, Takei A, Fukuzawa K, Kiuchi K, Takami K, et al. Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay. J Interv Card Electrophysiol. 2013;37(3):223–31.
28. Maddox W, Kay GN, Yamada T, Osorio J, Doppalapudi H, Plumb VJ, et al. Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2013;24(8):861–5.
29. Nagao T, Inden Y, Yanagisawa S, Kato H, Ishikawa S, Okumura S, et al. Differences in activated clotting time among uninterrupted anticoagulants during the periprocedural period of atrial fibrillation ablation. Heart Rhythm. 2015;12(9):1972–8.
30. Di Biase L, Lakkireddy D, Trivedi C, Deneke T, Martinek M, Mohanty S, et al. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study. Heart Rhythm. 2015;12(6):1162–8.
31. Lakkireddy D, Reddy YM, Di Biase L, Vallakati A, Mansour MC, Santangeli P, et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2014;63(10):982–8.
32. Somani R, Mohajer K, Haley C, Simpson CS, Abdollah H, Baranchuk A, et al. The peri-procedural use of dabigatran in patients undergoing left atrial ablation for atrial fibrillation. Cardiovasc Ther. 2014;32(5):198–201.
33. Nin T, Sairaku A, Yoshida Y, Kamiya H, Tatematsu Y, Nanasato M, et al. A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. Pacing Clin Electrophysiol. 2013;36(2):172–9.
34. Stepanyan G, Badhwar N, Lee RJ, Marcus GM, Lee BK, Tseng ZH, et al. Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation. J Interv Card Electrophysiol. 2014;40(1):33–8.
35. Bassiouny M, Saliba W, Rickard J, Shao M, Sey A, Diab M, et al. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ: Arrhythm Electrophysiol. 2013;6(3):460–4.
36. Yamaji H, Murakami T, Hina K, Higashiya S, Kawamura H, Murakami M, et al. Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation. Clin Drug Investig. 2013;33(6):409–18.
37. Santarpia G, De Rosa S, Polimeni A, Giampa S, Micieli M, Curcio A, et al. Efficacy and safety of non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis. PLoS One. 2015;10(5), e0126512.
38. Dillier R, Ammar S, Hessling G, Kaess B, Pavaci H, Buiatti A, et al. Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures. Circ Arrhythm Electrophysiol. 2014;7(4):576–82.
39. Kaess BM, Ammar S, Reents T, Dillier R, Lennerz C, Semmler V, et al. Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon. Am J Cardiol. 2015;115(1):47–51.
40. Sardar P, Nairooz R, Chatterjee S, Wetterslev J, Ghosh J, Aronow WS. Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. Am J Cardiol. 2014;113(7):1173–7.
41. Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013;61(19):1998–2006.